Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2008

View Archived Issues

D-Cycloserine does not affect social withdrawal in autistic children

Recent patents impart new therapeutic agents for cancer

FDA approves Hawaii Biotech's West Nile vaccine study in healthy volunteers

Dosing begins in Japanese AEGIS registration study of Soliris for PNH

BioSante begins phase III study of LibiGel for female hypoactive sexual desire disorder

Allos initiates phase IIb study of PDX in patients with non-small cell lung cancer

Phase II clinical study of MORAb-009 for pancreatic cancer begins

Exelixis initiates phase I/II trial of XL-184 for non-small cell lung cancer

Melanin-concentrating hormone, a potential antidepressant target

New ferritin light chain gene mutant mice, useful to study neuroferritinopathy / News in Context

Phase II clinical trial of Plicera for Gaucher disease gives positive results

Positive results from phase IIa clinical trial of MAXY-G34 for neutropenia

Orexigen reports positive 48-week results from phase IIb clinical trial of Empatic for obesity

Coronado initiates phase I trial of fourth-generation doxorubicin analogue

E.U. orphan drug status granted for RdCVF for retinitis pigmentosa

Ardea's lead NNRTI for HIV to enter phase IIa proof-of-concept trial

FDA approves Cialis for once daily use in treating erectile dysfunction

Novel agents for respiratory and allergic disorders claimed in recent patents

Two Movetis compounds successfully progressing through phase II clinical trials

Novel diagnostic agents disclosed by GE Healthcare

Ocera Therapeutics receives orphan drug status for AST-120 in pouchitis

Phase I trial commences for oxazolidinone antibacterial drug, TR-701

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...